The Von Hippel-Lindau Protein Interacts with Heteronuclear Ribonucleoprotein A2 and Regulates Its Expression*

The product of the von Hippel-Lindau (VHL) tumor suppressor gene, pVHL, functions as a ubiquitin-protein isopeptide ligase in regulating HIF-1 protein turnover, thus accounting for the increased transcription of hypoxia-inducible genes that accompanies VHL mutations. The increased vascular endothelial growth factor mRNA stability in cells lacking pVHL has been hypothesized to be due to a similar regulation of an RNA-binding protein. We report the expression of the GLUT-1 3′-untranslated region RNA-binding protein, heteronuclear ribonucleoprotein (hnRNP) A2, is specifically increased in pVHL-deficient cell lines. Enhanced hnRNP A2 expression was apparent in all cell fractions, including polysomes, where a similar modest effect on hnRNP L (a GLUT-1 and VEGF 3′-untranslated region-binding protein), was seen. Steady state levels of hnRNP A2 mRNA were unaffected. Regulation of hnRNP A2 levels correlated with the ability of pVHL to bind elongin C. Proteasome inhibition of cells expressing wild type pVHL selectively increased cytoplasmic hnRNP A2 levels to that seen in pVHL-deficient cells. Finally, an in vivo interaction between pVHL and hnRNP A2 was demonstrated in both the nucleus and the cytoplasm. Collectively, these data indicate that hnRNP A2 expression is regulated by pVHL in a manner that is dependent on elongin C interactions as well as functioning proteasomes.

[1]  G. Dreyfuss,et al.  Molecular characterization of the hnRNP A2/B1 proteins: tissue-specific expression and novel isoforms. , 1999, Experimental cell research.

[2]  M. Gstaiger,et al.  The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. , 1999, Genes & development.

[3]  T. Zhukov,et al.  Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  P. Jackson.  Cell cycle: Cull and destroy , 1996, Current Biology.

[5]  Y. Hamada,et al.  GLUT1 glucose transporter: differential gene transcription and mRNA binding to cytosolic and polysome proteins in brain and peripheral tissues. , 1998, Brain research. Molecular brain research.

[6]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[7]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. O. Poyton,et al.  Oxygen sensing and molecular adaptation to hypoxia. , 1996, Physiological reviews.

[9]  A. Kibel,et al.  Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. , 1997, Human pathology.

[10]  L. Poellinger,et al.  Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.

[11]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[12]  R. Conaway,et al.  Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[14]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[15]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[16]  G. Martiny-Baron,et al.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.

[17]  K. Plate,et al.  Putative Control of Angiogenesis in Hemangioblastomas by the von Hippel‐Lindau Tumor Suppressor Gene , 1997, Journal of neuropathology and experimental neurology.

[18]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[19]  J. Adamson,et al.  Polycythemia: mechanisms and management. , 1981, Annals of internal medicine.

[20]  Stephen Lee,et al.  Ran-mediated Nuclear Export of the von Hippel-Lindau Tumor Suppressor Protein Occurs Independently of Its Assembly with Cullin-2* , 2000, The Journal of Biological Chemistry.

[21]  R. Klausner,et al.  The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Kaelin,et al.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Pardridge,et al.  hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. , 1999, Biochemical and biophysical research communications.

[24]  K. Plate,et al.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.

[25]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[26]  W. Kaelin,et al.  The von Hippel-Lindau tumour suppressor protein: new perspectives. , 1999, Molecular medicine today.

[27]  M. Neeman,et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes , 1995, Molecular and cellular biology.

[28]  R. Schneider,et al.  Rapid degradation of AU-rich element (ARE) mRNAs is activated by ribosome transit and blocked by secondary structure at any position 5' to the ARE , 1995, Molecular and cellular biology.

[29]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[30]  Y. Nakamura,et al.  Specific genetic change in tumors associated with von Hippel-Lindau disease. , 1989, Journal of the National Cancer Institute.

[31]  K. Claffey,et al.  Regulation of Human Vascular Endothelial Growth Factor mRNA Stability in Hypoxia by Heterogeneous Nuclear Ribonucleoprotein L* , 1999, The Journal of Biological Chemistry.

[32]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[33]  M. Goldberg,et al.  Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.

[34]  R. Klausner,et al.  Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein , 1999, Molecular and Cellular Biology.

[35]  B. Seizinger,et al.  Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. , 1994, American journal of human genetics.

[36]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[37]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[38]  J. Malter,et al.  Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences. , 1993, The Journal of biological chemistry.

[39]  B. Seizinger,et al.  Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity , 1999, Oncogene.

[40]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[41]  C. Dang,et al.  Oncogenes in Tumor Metabolism, Tumorigenesis, and Apoptosis , 1997, Journal of bioenergetics and biomembranes.

[42]  S. Johnson,et al.  Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins , 1996, Molecular and cellular biology.

[43]  S. Elledge,et al.  Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. , 1999, Science.

[44]  C. Burd,et al.  RNA binding specificity of hnRNP A1: significance of hnRNP A1 high‐affinity binding sites in pre‐mRNA splicing. , 1994, The EMBO journal.

[45]  R. Klausner,et al.  Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Burk,et al.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[48]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[49]  D. Duan,et al.  Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.

[50]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Mike Tyers,et al.  Cdc53 Targets Phosphorylated G1 Cyclins for Degradation by the Ubiquitin Proteolytic Pathway , 1996, Cell.

[52]  G. Shaw,et al.  A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation , 1986, Cell.

[53]  R. Burk,et al.  Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Mulshine,et al.  Purification and Characterization of a Protein That Permits Early Detection of Lung Cancer , 1996, The Journal of Biological Chemistry.

[55]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[56]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[57]  W. Kaelin,et al.  Expression pattern of the von Hippel-Lindau protein in human tissues. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[58]  W. Kaelin,et al.  von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. , 1998, Cancer research.

[59]  R. Burk,et al.  VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling , 2001, Molecular and Cellular Biology.

[60]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Klausner,et al.  Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[63]  Stephen J. Elledge,et al.  SKP1 Connects Cell Cycle Regulators to the Ubiquitin Proteolysis Machinery through a Novel Motif, the F-Box , 1996, Cell.

[64]  W. Kaelin,et al.  Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2 , 1998, Molecular and Cellular Biology.